After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding
Hot off a provocative new set of clinical trial results, Intellia Therapeutics (NASDAQ: NTLA) and Editas Medicine (NASDAQ: EDIT) are surging. In the early-stage trial, Intellia's groundbreaking gene-editing therapy performed even better than expected, and it didn't seem to have a burdensome side-effect profile, either. So Editas, which is pursuing similar interventions, looks all the more promising.
What's more, Cathie Wood, of ARK Investment Management fame, holds both stocks. Such institutional backing is likely to expand even more. Though Intellia still has a long road ahead before its drug will be ready for regulatory review, it's off to a running start, and there's still plenty of time to invest.
Image source: Getty Images.
Source Fool.com
